Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Zeeshan Saeed TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on August 13, 2024 to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).
多倫多，ON / ACCESSWIRE / 2024年9月9日 / 量子生物製藥有限公司（納斯達克：QNTM）（CSE：QNTM）（FRA：0K91）（"量子生物製藥"或"公司"），一家致力於打造創新資產和生物技術解決方案組合的生物製藥公司，今天宣佈其子公司澳大利亞HUGE生物製藥有限公司於2024年8月13日與Ingenu CRO Pty Ltd達成協議，開展臨床研究以觀察和量化原發性進行性多發性硬化症患者的疾病進展。此項研究將有助於未來進行Lucid-21-302（Lucid-MS）的2期臨床試驗。
"We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
"我們非常高興能與Ingenu CRO合作，開展對多發性硬化症患者的觀察性研究。這是一項重要研究，推動了我們的多發性硬化症研究計劃，並使我們更接近啓動Lucid-21-302的2期臨床試驗，" Quantum Biopharma的科學和臨床事務副總裁Andrzej Chruscinski博士說。
Contact Information
聯繫信息
Zeeshan Saeed
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
416-854-8884
Zeeshan Saeed
創始人，首席執行官兼董事會聯席主席
zsaeed@quantumbiopharma.com
416-854-8884
SOURCE: Quantum Biopharma Ltd.
來源：Quantum Biopharma Ltd.
